1. Home
  2. MIN vs IKT Comparison

MIN vs IKT Comparison

Compare MIN & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Intermediate Income Trust

MIN

MFS Intermediate Income Trust

N/A

Current Price

$13.91

Market Cap

261.4M

Sector

Finance

ML Signal

N/A

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$1.51

Market Cap

209.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MIN
IKT
Founded
1988
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.4M
209.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MIN
IKT
Price
$13.91
$1.51
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $6.00
AVG Volume (30 Days)
29.2K
★ 587.6K
Earning Date
01-01-0001
11-10-2026
Dividend Yield
★ 7.31%
N/A
EPS Growth
N/A
★ 57.76
EPS
★ 0.08
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$55.55
P/E Ratio
$174.75
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.27
$1.40
52 Week High
$14.39
$2.61

Technical Indicators

Market Signals
Indicator
MIN
IKT
Relative Strength Index (RSI) 79.89 41.17
Support Level $13.74 $1.48
Resistance Level $14.28 $1.72
Average True Range (ATR) 0.14 0.11
MACD -0.43 0.02
Stochastic Oscillator 9.91 23.73

Price Performance

Historical Comparison
MIN
IKT

About MIN MFS Intermediate Income Trust

Aberdeen Intermediate Income Fund is a diversified, closed-end fixed-income management investment company. The fund's investment objective is to seek high current income, but may also consider capital appreciation.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: